TANABE PHARMA Trademark

Trademark Overview


On Thursday, May 21, 2026, a trademark application was filed for TANABE PHARMA with the United States Patent and Trademark Office. The USPTO has given the TANABE PHARMA trademark a serial number of 99837703. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, May 21, 2026. This trademark is owned by Tanabe Pharma Corporation. The TANABE PHARMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological , psychiatric and immune system related diseases and disorders; antiallergic medicines; antihypertensives; hypoglycemic agents; antidiabetic preparations; pharmaceutical preparations for the prevention of diabetic nephropathy; pharmaceutical preparations, namely, antiphlogistic agents; vaccine; pharmaceutical preparations for the treatment of autoimmune disease; pharmaceutical preparations for the treatment of cerebral infarction; pharmaceutical prepa...
tanabe pharma

General Information


Serial Number99837703
Word MarkTANABE PHARMA
Filing DateThursday, May 21, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, May 21, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkTANABE PHARMACEUTICAL
Goods and ServicesPharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological , psychiatric and immune system related diseases and disorders; antiallergic medicines; antihypertensives; hypoglycemic agents; antidiabetic preparations; pharmaceutical preparations for the prevention of diabetic nephropathy; pharmaceutical preparations, namely, antiphlogistic agents; vaccine; pharmaceutical preparations for the treatment of autoimmune disease; pharmaceutical preparations for the treatment of cerebral infarction; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of erectile dysfunction.
Pseudo MarkTANABE PHARMACEUTICALS

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 21, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTanabe Pharma Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressOsaka 541-8505
JP

Trademark Events


Event DateEvent Description
Thursday, May 21, 2026NEW APPLICATION ENTERED
Thursday, May 21, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 21, 2026APPLICATION FILING RECEIPT MAILED